8-K: Johnson & Johnson Reports Strong Q4, Full-Year 2025 Results

Johnson & Johnson announced robust fourth-quarter and full-year 2025 financial results, driven by strong operational growth and significant innovation across its Innovative Medicine and MedTech segments.

Summary

• Reported sales for the fourth quarter of 2025 increased by 9.1% to $24.6 Billion, with operational growth of 7.1% and adjusted operational growth of 6.1%.
• Fourth-quarter 2025 earnings per share (EPS) were $2.10, and adjusted EPS were $2.46, both including a $(0.10) impact from the acquisition of Halda Therapeutics.
• Full-year 2025 reported sales grew by 6.0% to $94.2 Billion, with operational growth of 5.3% and adjusted operational growth of 4.2%.
• Full-year 2025 EPS were $11.03, and adjusted EPS were $10.79, both including a $(0.10) impact from the acquisition of Halda Therapeutics.
• Innovative Medicine worldwide operational sales grew 5.3% for the full year, primarily driven by DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA, SIMPONI/SIMPONI ARIA, and SPRAVATO.
• MedTech worldwide operational sales grew 5.4% for the full year, primarily driven by electrophysiology products, Abiomed, and wound closure products.
• Significant innovation included approvals for CAPLYTA (major depressive disorder), RYBREVANT FASPRO plus LAZCLUZE (non-small cell lung cancer), AKEEGA (BRCA2-mutated metastatic castration-sensitive prostate cancer), DARZALEX FASPRO (high-risk smoldering multiple myeloma), and TRUFILL n-BCA Liquid Embolic System (symptomatic chronic subdural hematoma).
• Landmark data was reported for TECVAYLI plus DARZALEX FASPRO as a potential standard of care for relapsed/refractory multiple myeloma.
• The company completed the acquisition of Halda Therapeutics and submitted the OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration (FDA).
• Guidance for 2026 estimates reported sales of $100.5 Billion (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint).
• The company announced its intent to separate its Orthopaedics business.

Sentiment

Score: 8

Explanation: The filing reports strong financial results for both the quarter and the full year, with significant growth in sales and earnings. It highlights numerous product approvals, landmark clinical data, and strategic acquisitions, indicating a robust pipeline and strong market position. The positive outlook for 2026 further reinforces a strong sentiment.

Positives

• Reported sales for Q4 2025 increased by 9.1% to $24.6 Billion, demonstrating strong quarterly performance.
• Full-year 2025 reported sales grew by 6.0% to $94.2 Billion, indicating robust annual growth.
• Net earnings for Q4 2025 surged by 49.1% to $5,116 Million, and full-year 2025 net earnings increased by 90.6% to $26,804 Million.
• Adjusted EPS for Q4 2025 grew by 20.6% to $2.46, and full-year 2025 adjusted EPS increased by 8.1% to $10.79.
• Innovative Medicine and MedTech segments both showed strong full-year operational sales growth of 5.3% and 5.4% respectively.
• Key growth drivers include DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA, SIMPONI/SIMPONI ARIA, SPRAVATO, electrophysiology products, Abiomed, and wound closure products.
• Multiple significant regulatory approvals were secured, including CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer.
• Landmark clinical data was unveiled for TECVAYLI plus DARZALEX FASPRO, positioning it as a potential standard of care for relapsed/refractory multiple myeloma.
• The acquisition of Halda Therapeutics enhances the company's oncology pipeline with a novel platform for cancer treatment.
• The submission of the OTTAVA Robotic Surgical System to the FDA signals continued innovation in MedTech.
• The company issued strong guidance for 2026, projecting continued sales and adjusted EPS growth.

Negatives

• STELARA in Immunology had a significant negative impact on Innovative Medicine growth, approximately (1,040) basis points for the full year.
• IMBRUVICA sales declined by (17.4%) in Q4 2025 U.S. and (12.5%) for Full-Year 2025 U.S.
• ZYTIGA/abiraterone acetate sales declined by (41.4%) in Q4 2025 U.S. and (33.2%) for Full-Year 2025 U.S.
• CONCERTA/methylphenidate sales declined by (79.6%) in Q4 2025 U.S. and (38.6%) for Full-Year 2025 U.S.
• INVEGA SUSTENNA/XEPLION/INVEGATRINZA/TREVICTA sales declined by (11.5%) in Q4 2025 U.S. and (12.8%) for Full-Year 2025 U.S.
• Restructuring expenses related to the Orthopaedics franchise amounted to $162 million in Q4 2025 and $307 million year-to-date.
• Restructuring expenses related to the Surgery franchise amounted to $48 million in Q4 2025 and $205 million year-to-date.
• The acquisition of Halda Therapeutics had a negative impact of $(0.10) on both Q4 and Full-Year 2025 EPS and adjusted EPS.

Risks

• Economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations.
• Competition, including technological advances, new products and patents attained by competitors.
• Challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals.
• Uncertainty of commercial success for new and existing products.
• Challenges to patents and the impact of patent expirations.
• The ability to successfully execute strategic plans, including restructuring plans.
• The impact of business combinations and divestitures.
• Manufacturing difficulties or delays, internally or within the supply chain.
• Product efficacy or safety concerns resulting in product recalls or regulatory action.
• Significant adverse litigation or government action, including related to product liability claims.
• Changes to applicable laws and regulations, including tax laws and global health care reforms.
• Trends toward health care cost containment.
• Changes in behavior and spending patterns of purchasers of health care products and services.
• Financial instability of international economies and legal systems and sovereign risk.
• Increased scrutiny of the health care industry by government agencies.

Future Outlook

Johnson & Johnson issued guidance for 2026, estimating reported sales of $100.5 Billion at the midpoint, representing 6.7% growth. Adjusted EPS is projected at $11.53 at the midpoint, indicating 6.9% growth. Adjusted operational sales growth is expected to be between 5.4% and 6.4%, and operational sales growth between 5.7% and 6.7%.

Management Comments

• "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history." Joaquin Duato, Chairman and Chief Executive Officer.
• "Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision."
• "In each of these important areas, our leadership is expanding driven by game-changing science and technology."

Industry Context

Johnson & Johnson's strong performance, particularly in its Innovative Medicine and MedTech segments, aligns with a broader industry trend of growth fueled by advancements in novel therapies and medical technologies. The company's strategic focus on high-growth therapeutic areas like oncology, immunology, and neuroscience, coupled with innovation in cardiovascular and surgical solutions, positions it well within the competitive healthcare landscape. The acquisition of Halda Therapeutics and the submission of the OTTAVA Robotic Surgical System underscore a commitment to leading-edge innovation. The announced intent to separate the Orthopaedics business suggests a strategic portfolio optimization, a common move among large diversified healthcare companies seeking to enhance focus and unlock value in core growth areas.

Corporate Governance

Legal Proceedings

• The reconciliation of non-GAAP financial measures includes pre-tax adjustments for 'Litigation related' items of $854 million in Q4 2025 and $(6,040) million for Full-Year 2025, indicating ongoing legal matters impacting financial results.

Stakeholder Impact

• Shareholders are likely to benefit from strong financial performance, increased EPS, positive future guidance, and strategic initiatives like the Orthopaedics separation, which could unlock value.
• Employees in the Orthopaedics and Surgery segments may be impacted by restructuring programs involving streamlining operations and exiting certain product lines/markets.
• Customers will benefit from new product approvals and innovations across various therapeutic areas (Oncology, Immunology, Neuroscience) and MedTech, offering advanced treatment options.
• Suppliers may experience adjustments in supply chain relationships due to restructuring programs and the planned business separation.
• Creditors are likely to view the company's strong financial health and positive outlook favorably, suggesting continued ability to meet financial obligations.

Next Steps

• Johnson & Johnson will conduct a conference call with investors on January 21, 2026, at 8:30 a.m., Eastern Time.
• A replay and podcast of the conference call will be available approximately two hours after the live webcast.
• The Surgery restructuring program is expected to be substantially completed by the end of fiscal year 2026.
• The company intends to separate its Orthopaedics business.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with significant growth in both sales and earnings for Q4 and Full-Year 2025, exceeding prior year results. The robust pipeline, evidenced by numerous regulatory approvals and landmark clinical data across key therapeutic areas, positions the company for sustained innovation and market leadership. Strategic moves like the acquisition of Halda Therapeutics and the planned separation of the Orthopaedics business are expected to enhance focus and unlock shareholder value. The strong 2026 guidance further reinforces confidence in future growth. Despite some product declines and restructuring costs, the overall trajectory and strategic execution warrant a "Strong Buy" recommendation.

Keywords

Johnson & Johnson, JNJ, Q4 2025, Full-Year 2025, earnings, sales, Innovative Medicine, MedTech, pharmaceuticals, medical devices, oncology, immunology, neuroscience, cardiovascular, surgery, vision, CAPLYTA, RYBREVANT, LAZCLUZE, TECVAYLI, DARZALEX, CARVYKTI, TREMFYA, STELARA, Halda Therapeutics, OTTAVA Robotic Surgical System, FDA approval, clinical data, guidance, healthcare, biotech, pharma